ABC | Volume 113, Nº2, August 2019

Short Editorial Spineti Biomarkers in heart failure Arq Bras Cardiol. 2019; 113(2):205-206 1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95. 2. Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation. 2007;115(8):949– 952. 3. Chow SL, Maisel AS, Anand I, Bozkurt B, de Boer RA, Felker GM, et al. Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the AmericanHeart Association. Circulation. 2017; 135(22):e1054-e1091. 4. Comitê Coordenador da Diretriz de Insuficiência Cardíaca. Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda.Sociedade Brasileira de Cardiologia. Arq Bras Cardiol. 2018;111(3):436-539. 5. Molvin J, Jujic A, Bachus E, Gallo W , Tasevska-Dinevska G, Holm H, et al. Cardiovascular biomarkers predict post-discharge re-hospitalization risk and mortality among Swedish heart failure patients. ESCHeart Fail. 2019 Jul 24. [Epub ahead of print] 6. Jianlong Y, Yanbin P, Junhui X, Wenxue M, Li L, Zhong M, et al. High level of lipoprotein(a) as predictor for recurrent heart failure in patients with chronic heart failure: a Cohort Study. Arq Bras Cardiol. 2019; 113(2):197-204. References This is an open-access article distributed under the terms of the Creative Commons Attribution License 206